Zavicefta 2g/0.5g powder for concentrate for solution for infusion

  • Name:

    Zavicefta 2g/0.5g powder for concentrate for solution for infusion

  • Company:
    info
  • Active Ingredients:

    Ceftazidime Pentahydrate, Avibactam sodium

  • Legal Category:

    Product subject to medical prescription which may not be renewed (A)

Patient Information Leaflet Patient Information Leaflet last updated on medicines.ie: 06/12/19

files-icon(Click to Download)
Summary of Product Characteristics last updated on medicines.ie: 12/4/2019
This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 for how to report adverse reactions.

Click on this link to Download PDF directly

Pfizer Healthcare Ireland

Pfizer Healthcare Ireland

Company Products

Medicine NameActive Ingredients
Medicine Name Lipitor 80mg film-coated tablets Active Ingredients Atorvastatin calcium trihydrate
Medicine Name Loniten 5 mg Tablets Active Ingredients Minoxidil
Medicine Name LOPID 300MG CAPSULES Active Ingredients Gemfibrozil
Medicine Name Lopid 600 mg film-coated tablet Active Ingredients Gemfibrozil
Medicine Name Lorviqua 25mg & 100mg Film Coated Tablets Active Ingredients Lorlatinib
Medicine Name LUSTRAL 100 mg film coated tablets Active Ingredients sertraline hydrochloride
Medicine Name LUSTRAL 50mg film coated tablets Active Ingredients sertraline hydrochloride
Medicine Name LYRICA Capsules Active Ingredients pregabalin
Medicine Name Meronem I.V. 1g Active Ingredients Meropenem Trihydrate
Medicine Name Methotrexate 1 g/10 ml Injection Active Ingredients Methotrexate Sodium
Medicine Name Methotrexate 10 mg Tablets Active Ingredients Methotrexate
Medicine Name Methotrexate 2.5mg Tablets Active Ingredients Methotrexate
Medicine Name Methotrexate 5 g/50 ml Injection Active Ingredients Methotrexate Sodium
Medicine Name Methotrexate 5 mg/2 ml Injection Active Ingredients Methotrexate Sodium
Medicine Name Methotrexate 50 mg/2 ml Injection Active Ingredients Methotrexate
Medicine Name Methotrexate 500 mg/20 ml Injection Active Ingredients Methotrexate Sodium
Medicine Name Minulet 75 micrograms/30 micrograms Coated Tablets Active Ingredients Ethinylestradiol, Gestodene
Medicine Name Mitoxantrone 2 mg/ml Concentrate for Solution for Infusion Active Ingredients Mitoxantrone hydrochloride
Medicine Name Mycobutin Capsules Active Ingredients Rifabutin
Medicine Name MYLOTARG 5mg powder for concentrate for solution for infusion Active Ingredients Gemtuzumab ozogamicin
Medicine Name Neurontin 100mg Hard Capsules Active Ingredients Gabapentin
Medicine Name Neurontin 300mg Hard Capsules Active Ingredients Gabapentin
Medicine Name Neurontin 400mg Hard Capsules Active Ingredients Gabapentin
Medicine Name Neurontin 600mg Film-coated Tablets Active Ingredients Gabapentin
Medicine Name Neurontin 800mg Film-coated Tablets Active Ingredients Gabapentin
126 - 150 of 227 items.Total: 10 pages

When a pharmaceutical company changes any document, a new version is published on medicines.ie. For each version, we show the dates it was published on medicines.ie and the reasons for change.

Updated on 6 December 2019 PIL

Reasons for updating

  • Change to section 6 - date of revision

Updated on 15 April 2019 PIL

Reasons for updating

  • Change to section 6 - date of revision

Updated on 12 April 2019 SmPC

Reasons for updating

  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Updated on 31 October 2018 PIL

Reasons for updating

  • Change to section 6 - date of revision

Updated on 31 October 2018 SmPC

Reasons for updating

  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

The SPC has been updated as follows:

Section 10: DATE OF REVISION OF THE TEXT has been updated – (10/2018)

Updated on 25 July 2018 PIL

Reasons for updating

  • Change to section 2 - excipient warnings
  • Improved presentation of PIL

Updated on 25 July 2018 SmPC

Reasons for updating

  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.4 - Special warnings and precautions for use

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Sections 4.2 (Posology and method of administration) and 4.8 (Undesirable effects) updated following completion of the paediatric study C3591004.

Section 4.4 sodium statement updated to align with the Annex to the EU Commission guideline on ‘Excipients in the labelling and package leaflet of medicinal products for human use’.

Updated on 6 February 2018 SmPC

Reasons for updating

  • New SmPC for new product

Legal category: Product subject to medical prescription which may not be renewed (A)

Updated on 6 February 2018 SmPC

Reasons for updating

  • Change to section 7 - Marketing authorisation holder

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

The SPC has been updated as follows:
Section 7 - MA Holder address "Operations Services Group" corrected to "Operations Support Group".

Updated on 5 February 2018 PIL

Reasons for updating

  • New PIL for new product

Updated on 5 February 2018 PIL

Reasons for updating

  • Change to section 6 - marketing authorisation holder
  • Change to section 6 - date of revision

Updated on 8 January 2018 PIL

Reasons for updating

  • New PIL for new product

Updated on 8 January 2018 SmPC

Reasons for updating

  • New SPC for new product

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

None provided